指南与共识心血管外周血管技术与安全MR

西班牙动脉硬化学会(SEA)专家组的共识文件:关于核磁共振评估脂蛋白代谢(Liposcale®)的临床应用

Consensus document of an expert group from the Spanish Society of Arteriosclerosis (SEA) on the clinical use of nuclear magnetic resonance to assess lipoprotein metabolism (Liposcale®).
指南 / 共识 · Clin Investig Arterioscler · 2020-08-11

西班牙动脉硬化学会的脂质学家专家组综述了脂蛋白颗粒致动脉粥样硬化机制的现有证据,描述了通过核磁共振(NMR)获得的脂蛋白谱的技术基础和解读,特别提及西班牙可用的Liposcale®检测,并定义了最能从该分析中获得临床信息的患者特征。

要点

  • NMR可详细分析脂蛋白的数量、组成和大小,提供脂质代谢状态和心血管风险的额外信息。
  • 传统脂质生物标志物可能不足以准确评估心血管风险,尤其在糖尿病、肥胖和代谢综合征患者中。
  • 建议在怀疑脂质浓度与颗粒不匹配、早发或复发性动脉粥样硬化血栓性心血管疾病等情况下考虑NMR分析。

临床应用与阅片要点

  • 对于怀疑脂质浓度与颗粒不匹配的患者(如糖尿病、肥胖、代谢综合征),可考虑NMR分析以提供更多临床信息。
  • 对于早发或复发性动脉粥样硬化血栓性心血管疾病且无明确心血管风险因素的患者,可考虑NMR分析。
  • 对于罕见或复杂的脂质紊乱(如极端高密度脂蛋白胆固醇浓度)以及经典分析技术无法应用的情况(如极低低密度脂蛋白胆固醇值),可考虑NMR分析。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

The assessment and prevention of cardiovascular risk (CVR) that persists in patients with dyslipidaemia despite treatment and achievement of goals specific to the plasma concentration of cholesterol linked to low density (c-LDL) is a clinical challenge today, and suggests that conventional lipid biomarkers are insufficient for an accurate assessment of CVR. Apart from their lipid content, there are other lipid particle characteristics. The results of this study show that there are a number of lipoprotein compounds that determine atherogenic potential and its influence on the CVR. However, such additional characteristics cannot be analysed by the techniques commonly used in clinical laboratories. Nuclear Magnetic Resonance (NMR) is a technique that allows a detailed analysis to be made of the amount, composition, and size of lipoproteins, as well as providing more information about the detailed status of lipid metabolism and CVR in dyslipidaemia patients. In this article a group of lipidologists from the Spanish Society of Arteriosclerosis review the existing evidence on the atherogenic mechanisms of particles and describe the technical basis and interpretation of the profiles lipoproteins obtained by MRI, with special reference to the test available in Spain (Liposcale®). Likewise, the main patient profiles are defined as such that an analysis would provide information of greater clinical interest. These include: a) Suspected mismatch between lipid concentrations and particles, a common situation in diabetes, obesity, metabolic syndrome; b) Early atherothrombotic cardiovascular disease (ECVA) or recurrent without CVR factors to justify it; c) Lipid disorders, rare or complex, such as extreme concentrations of c-HDL, and d) Clinical situations where classical analytical techniques cannot be applied, such as very low c-LDL values.

来源:Clin Investig Arterioscler,查看原文。版权归原作者所有。

引用

  1. Pintó X, Masana L, Civeira F, et al. Consensus document of an expert group from the Spanish Society of Arteriosclerosis (SEA) on the clinical use of nuclear magnetic resonance to assess lipoprotein metabolism (Liposcale®). Clin Investig Arterioscler. 2020. PMID: 32798078. doi:10.1016/j.arteri.2020.04.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。